Chapter 8

The Treatment of Patients with Preclinical Atherosclerosis: Beyond the Progetto Cuore’s Card of Risk

S. Novo, G.R. Amoroso, F. Bonura, P. Carità, E. Corrado and G. Novo

Abstract

According to the Progetto Cuore, subjects with at least 2 or 3 RF are currently considered at intermediate risk. Recently, we demonstrated that the instrumental evidence of preclinical ATS (IMT/ACP) puts these patients into a higher category of risk. The consequent implications in clinical practice are very important: more aggressive pharmacological strategies could be useful, even if this recommendation is not yet unanimous. The inclusion of carotid IMT assessment in the "Progetto Cuore's" cards could provide further information for a better determination of GCVR and for a more aggressive pharmacological primary prevention.

Total Pages: 59-62 (4)

Purchase Chapter  Book Details

RELATED BOOKS

.Cardiac Care and COVID-19: Perspectives in Medical Practice.
.Nanomedicinal Approaches Towards Cardiovascular Disease.
.Pharmacotherapeutic Management of Cardiovascular Disease Complications: A Textbook for Medical Students.
.Perinatal Cardiology-Part 1.